Eli Lilly and Company (NYSE:LLY) is expanding its neuroscience pipeline through the acquisition of SiteOne Therapeutics in a deal worth up to $1 billion, deepening its bet on non-opioid pain ...

Lending support to his choice, Rocket Companies, on May 8, posted better-than-expected quarterly sales. Markets expect rate ...

CNBC’s Jim Cramer on Friday detailed how President Donald Trump’s global trade decisions seriously inhibit two of the U.S.’s biggest tech titans.

Eli Lilly, Navitas, Red Cat, Mr. Cooper, Rocket, Liberty Energy, Rio Tinto, and DeFi Development. Russia Calls Trump ...

CNBC's Jim Cramer on Friday guided investors through next week on Wall Street, saying quarterly reports from Nvidia, Costco, Dell and Salesforce have the potential to move their respective sectors and ...

Mad Money” host Jim Cramer rings the lightning round bell, which means he’s giving his answers to callers’ stock questions at ...

Cigna’s Evernorth has introduced a new pharmacy benefit that caps out-of-pocket costs for GLP-1 weight loss medications at $200 per month, in a move analysts say is more favorable for Eli Lilly ...

As its obesity medication Wegovy loses a sizable portion of the market to Eli Lilly and Company (NYSE:LLY)’s competing medicine, Zepbound, the Danish pharmaceutical behemoth Novo Nordisk A/S (NYSE:NVO ...

Eli Lilly (LLY) is a leading pharmaceutical company that discovers, develops, manufactures, and markets healthcare products.

We recently published a list of 13 Stocks on Jim Cramer’s Radar Recently. In this article, we are going to take a look at ...

At the Tegernsee summit, business leaders urged Germany’s new government to turn campaign promises into reality.

We recently published an article titled Jim Cramer Says AI Is Back & Discusses These 10 Stocks. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against ...